Jun Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jun Li has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Alexandre Reuben
Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center
3 shared publications - Andrew Futreal
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA
3 shared publications - Boris Sepesi
Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
3 shared publications - Cara Haymaker
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
3 shared publications - Carmen Behrens
Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
3 shared publications - Chang-Jiun Wu
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA
3 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Bentham Science Publishers Ltd. in Current HIV Research
- Vol. 24 (1) , 1-16
HIV-Associated Lymphomas: Updates from Pathogenesis to Treatment Strategies
HIV-associated lymphoma (HAL) is an aggressive malignancy directly linked to HIV infection and accounts for more than 30% of cancer-related deaths in people living with HIV (PLWH). HAL subtypes, including diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), primary effusion lymphoma (PEL), and plasmablastic lymphoma (PBL), exhibit five to ten times higher incidence rates and distinct molecular profiles compared to HIV-negative lympho-mas. Pathogenesis involves HIV-driven CD4+ T-cell depletion, chronic B-cell activation, and on-cogenic viral coinfection. First-line therapy combines antiretroviral therapy (ART) with chemo-therapy, achieving complete remission rates of 60-70% for DLBCL using R-EPOCH and 50-60% for BL with CODOX-M/IVAC. Relapsed/refractory cases show durable responses to CD19-CAR-T therapy; however, only 10% of HAL patients are enrolled in pivotal immunotherapy tri-als. Severe immunosuppression necessitates PET-CT-guided de-escalation and nanoparticle-based drug delivery systems to minimize toxicity. Emerging strategies include PD-1 inhibitors and broad-spectrum antivirals targeting HIV reservoirs, underscoring the need for precision med-icine that integrates tumor genomics and viral dynamics.
- 1 January 2026
- Published by Bentham Science Publishers Ltd. in Current HIV Research
- Vol. 24 (1) , 1-16
Open AccessHIV-Associated Lymphomas: Updates from Pathogenesis to Treatment Strategies
HIV-associated lymphoma (HAL) is an aggressive malignancy directly linked to HIV infection and accounts for more than 30% of cancer-related deaths in people living with HIV (PLWH). HAL subtypes, including diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), primary effusion lymphoma (PEL), and plasmablastic lymphoma (PBL), exhibit five to ten times higher incidence rates and distinct molecular profiles compared to HIV-negative lympho-mas. Pathogenesis involves HIV-driven CD4+ T-cell depletion, chronic B-cell activation, and on-cogenic viral coinfection. First-line therapy combines antiretroviral therapy (ART) with chemo-therapy, achieving complete remission rates of 60-70% for DLBCL using R-EPOCH and 50-60% for BL with CODOX-M/IVAC. Relapsed/refractory cases show durable responses to CD19-CAR-T therapy; however, only 10% of HAL patients are enrolled in pivotal immunotherapy tri-als. Severe immunosuppression necessitates PET-CT-guided de-escalation and nanoparticle-based drug delivery systems to minimize toxicity. Emerging strategies include PD-1 inhibitors and broad-spectrum antivirals targeting HIV reservoirs, underscoring the need for precision med-icine that integrates tumor genomics and viral dynamics.
- 10 August 2023
- Published by Springer Nature in Neurosurgical Review
- Vol. 46 (1) , 1-9
A novel flow diverter device (Tubridge) for the treatment of intracranial aneurysms: a systematic review and meta-analysis
The flow diverter (FD) device has become a feasible and effective option for treating intracranial aneurysms. This study aimed to evaluate the efficacy and safety of Tubridge FD (TFD) in treating intracranial aneurysms and provide evidence for further research and clinical application. Electronic databases, including PubMed, Web of Science, Embase, and the Cochrane Library from inception to July 31, 2022, were searched. The eligible studies should include TFD investigations in treating intracranial aneurysms. Pooled technical success rate, complete occlusion rate, improvement rate, stable rate, symptom elimination rate, and adverse events rate were calculated with either the fixed-effects model or the random-effects model, depending on the results of tests for heterogeneity. Egger’s tests were performed to assess the potential publication bias. A total of 7 studies (145 patients) were included in this study. The pooled technical success rate was 0.98, the complete occlusion rate was 0.79, the improvement rate was 0.21, and the stable rate was 0.05. One included study reported that the surgery-related mortality rate in the Tubridge group was higher than that in the control group (3.66% vs. 1.61%), while the surgery-related morbidity rate in the Tubridge group was 2.4% and that in the control group was 0. Findings of this meta-analysis indicate that TFD manifests promising and effective performance with acceptable adverse events in the treatment of intracranial aneurysms.
- 10 August 2023
- Published by Springer Nature in Neurosurgical Review
- Vol. 46 (1) , 1-9
A novel flow diverter device (Tubridge) for the treatment of intracranial aneurysms: a systematic review and meta-analysis
The flow diverter (FD) device has become a feasible and effective option for treating intracranial aneurysms. This study aimed to evaluate the efficacy and safety of Tubridge FD (TFD) in treating intracranial aneurysms and provide evidence for further research and clinical application. Electronic databases, including PubMed, Web of Science, Embase, and the Cochrane Library from inception to July 31, 2022, were searched. The eligible studies should include TFD investigations in treating intracranial aneurysms. Pooled technical success rate, complete occlusion rate, improvement rate, stable rate, symptom elimination rate, and adverse events rate were calculated with either the fixed-effects model or the random-effects model, depending on the results of tests for heterogeneity. Egger’s tests were performed to assess the potential publication bias. A total of 7 studies (145 patients) were included in this study. The pooled technical success rate was 0.98, the complete occlusion rate was 0.79, the improvement rate was 0.21, and the stable rate was 0.05. One included study reported that the surgery-related mortality rate in the Tubridge group was higher than that in the control group (3.66% vs. 1.61%), while the surgery-related morbidity rate in the Tubridge group was 2.4% and that in the control group was 0. Findings of this meta-analysis indicate that TFD manifests promising and effective performance with acceptable adverse events in the treatment of intracranial aneurysms.
- Open Access
- 5 May 2023
- Published by Asploro Open Access Publications in Asploro Journal of Biomedical and Clinical Case Reports
- Vol. 6 (2) , 87-90
Ultrasound-Guided Pericapsular Nerve Group (PENG) Block Combined with Lateral Femoral Cutaneous Nerve Block for Total Hip Arthroplasty
With the arrival of an aging society and the progress of surgical procedures, total hip arthroplasty (THA) has been carried out more and more. However, postoperative pain severely affected the patient’s recovery, and there is currently no reliable analgesic method available. Evidence-based international expert consensus also recommends, compared to LIA, peripheral nerve block (PNB) as a central analgesic approach use in THA for improved outcomes [1]. In this case report, we described 4 cases of postoperative analgesia with pericapsular nerve group (PENG) block combined with lateral femoral cutaneous nerve block (LFCNB) in patients undergoing THA.
- 5 May 2023
- Published by Asploro Open Access Publications in Asploro Journal of Biomedical and Clinical Case Reports
- Vol. 6 (2) , 87-90
Open AccessUltrasound-Guided Pericapsular Nerve Group (PENG) Block Combined with Lateral Femoral Cutaneous Nerve Block for Total Hip Arthroplasty
With the arrival of an aging society and the progress of surgical procedures, total hip arthroplasty (THA) has been carried out more and more. However, postoperative pain severely affected the patient’s recovery, and there is currently no reliable analgesic method available. Evidence-based international expert consensus also recommends, compared to LIA, peripheral nerve block (PNB) as a central analgesic approach use in THA for improved outcomes [1]. In this case report, we described 4 cases of postoperative analgesia with pericapsular nerve group (PENG) block combined with lateral femoral cutaneous nerve block (LFCNB) in patients undergoing THA.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence
Genomic intratumor heterogeneity (ITH) may be associated with postsurgical relapse of localized lung adenocarcinomas. Recently, mutations, through generation of neoantigens, were shown to alter tumor immunogenicity through T-cell responses. Here, we performed sequencing of the T-cell receptor (TCR) in 45 tumor regions from 11 localized lung adenocarcinomas and observed substantial intratumor differences in T-cell density and clonality with the majority of T-cell clones restricted to individual tumor regions. TCR ITH positively correlated with predicted neoantigen ITH, suggesting that spatial differences in the T-cell repertoire may be driven by distinct neoantigens in different tumor regions. Finally, a higher degree of TCR ITH was associated with an increased risk of postsurgical relapse and shorter disease-free survival, suggesting a potential clinical significance of T-cell repertoire heterogeneity.Significance: The present study provides insights into the ITH of the T-cell repertoire in localized lung adenocarcinomas and its potential biological and clinical impact. The results suggest that T-cell repertoire ITH may be tightly associated to genomic ITH and disease relapse. Cancer Discov; 7(10); 1088–97. ©2017 AACR.This article is highlighted in the In This Issue feature, p. 1047
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence
Genomic intratumor heterogeneity (ITH) may be associated with postsurgical relapse of localized lung adenocarcinomas. Recently, mutations, through generation of neoantigens, were shown to alter tumor immunogenicity through T-cell responses. Here, we performed sequencing of the T-cell receptor (TCR) in 45 tumor regions from 11 localized lung adenocarcinomas and observed substantial intratumor differences in T-cell density and clonality with the majority of T-cell clones restricted to individual tumor regions. TCR ITH positively correlated with predicted neoantigen ITH, suggesting that spatial differences in the T-cell repertoire may be driven by distinct neoantigens in different tumor regions. Finally, a higher degree of TCR ITH was associated with an increased risk of postsurgical relapse and shorter disease-free survival, suggesting a potential clinical significance of T-cell repertoire heterogeneity.Significance: The present study provides insights into the ITH of the T-cell repertoire in localized lung adenocarcinomas and its potential biological and clinical impact. The results suggest that T-cell repertoire ITH may be tightly associated to genomic ITH and disease relapse. Cancer Discov; 7(10); 1088–97. ©2017 AACR.This article is highlighted in the In This Issue feature, p. 1047
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Figures S1-S11 from TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence
Supplemental Figure S1. Number of predicted neoantigens. Supplemental Figure S2. Association between expressed branch predicted neoantigens and relapse. Supplemental Figure S3. Substantial ITH in the number of unique T cell rearrangements. Supplemental Figure S4. Substantial ITH in tumor-enriched T cell repertoire in 8 patients whose blood samples were available. Supplemental Figure S5. A minority of T cell clones are shared between different regions within a tumor. Supplemental Figure S6. The top 5 clones within each tumor are conserved across all regions of that given tumor. Supplemental Figure S7. Tumor-enriched MOI in patients with available paired blood. Supplemental Figure S8. CD4-dominant T cell infiltrate in localized lung adenocarcinomas by immunohistochemical (IHC) staining. Supplemental Figure S9. Correlation between predicted neoantigen burden and TCR metrics. Supplemental Figure S10. Association between intratumor TCR heterogeneity and patient relapse. Supplemental Figure S11. Follow up time (months) in patients who recurred and those who have not. n.s., not significant.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figures S1-S11 from TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence
Supplemental Figure S1. Number of predicted neoantigens. Supplemental Figure S2. Association between expressed branch predicted neoantigens and relapse. Supplemental Figure S3. Substantial ITH in the number of unique T cell rearrangements. Supplemental Figure S4. Substantial ITH in tumor-enriched T cell repertoire in 8 patients whose blood samples were available. Supplemental Figure S5. A minority of T cell clones are shared between different regions within a tumor. Supplemental Figure S6. The top 5 clones within each tumor are conserved across all regions of that given tumor. Supplemental Figure S7. Tumor-enriched MOI in patients with available paired blood. Supplemental Figure S8. CD4-dominant T cell infiltrate in localized lung adenocarcinomas by immunohistochemical (IHC) staining. Supplemental Figure S9. Correlation between predicted neoantigen burden and TCR metrics. Supplemental Figure S10. Association between intratumor TCR heterogeneity and patient relapse. Supplemental Figure S11. Follow up time (months) in patients who recurred and those who have not. n.s., not significant.
- 6 December 2021
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 63 (5) , 1167-1179
RIPK1 inhibition enhances the therapeutic efficacy of chidamide in FLT3-ITD positive AML, both in vitro and in vivo
Acute myeloid leukemia (AML) with FLT3-ITD mutation accounts for a large proportion of relapsed/refractory AML with poor prognosis. RIPK1 is a known key regulator of necroptosis and RIPK1 inhibition shows anti-AML effects in vitro. Chidamide is a histone deacetylase inhibitor (HDACi) with proven ability to induce apoptosis in FLT3-ITD positive AML cells. In the present study, we evaluated the effects of the combination of 22b, a novel RIPK1 inhibitor, and chidamide on proliferation and apoptosis in FLT3-ITD positive AML cell lines and primary cells. The results showed that 22b could significantly enhance the anti-leukemia effect of low-dose chidamide both on cell lines and primary cells. In a subcutaneous xenograft AML model, the combination of 22b and chidamide exhibited obviously elevated anti-tumor activity. In conclusion, our results support that the combination of RIPK1 inhibitor 22b and chidamide may be a novel therapeutic avenue for FLT3-ITD positive AML patients.
- 6 December 2021
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 63 (5) , 1167-1179
RIPK1 inhibition enhances the therapeutic efficacy of chidamide in FLT3-ITD positive AML, both in vitro and in vivo
Acute myeloid leukemia (AML) with FLT3-ITD mutation accounts for a large proportion of relapsed/refractory AML with poor prognosis. RIPK1 is a known key regulator of necroptosis and RIPK1 inhibition shows anti-AML effects in vitro. Chidamide is a histone deacetylase inhibitor (HDACi) with proven ability to induce apoptosis in FLT3-ITD positive AML cells. In the present study, we evaluated the effects of the combination of 22b, a novel RIPK1 inhibitor, and chidamide on proliferation and apoptosis in FLT3-ITD positive AML cell lines and primary cells. The results showed that 22b could significantly enhance the anti-leukemia effect of low-dose chidamide both on cell lines and primary cells. In a subcutaneous xenograft AML model, the combination of 22b and chidamide exhibited obviously elevated anti-tumor activity. In conclusion, our results support that the combination of RIPK1 inhibitor 22b and chidamide may be a novel therapeutic avenue for FLT3-ITD positive AML patients.
- Open Access
- 1 November 2018
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 24, 7809-7819
Pain Prevalence and Pain Management in a Chinese Hospital
BACKGROUND:Pain prevalence has been investigation in many developed countries, but integrated information about pain prevalence in Chinese hospitals is lacking. To achieve better pain treatment of hospitalized patients, pain management needs to be in...
- 1 November 2018
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 24, 7809-7819
Open AccessPain Prevalence and Pain Management in a Chinese Hospital
BACKGROUND:Pain prevalence has been investigation in many developed countries, but integrated information about pain prevalence in Chinese hospitals is lacking. To achieve better pain treatment of hospitalized patients, pain management needs to be in...
- 8 September 2010
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2010 (9) , CD005631
Heparin and related substances for preventing diabetic kidney disease
Diabetic kidney disease (DKD, also called diabetic nephropathy, DN) is the major cause of end-stage kidney disease (ESKD) in many countries and is associated with increased morbidity and mortality as compared to other causes of kidney disease. One of the pathological changes of DKD is the thickening of the glomerular basement membrane, mesangial expansion and proliferation. The presence of the glycosaminoglycan side chains of heparan sulfate proteoglycan, an important constituent of the glomerular basement membrane, is decreased in DKD proportionally to the increasing degree of proteinuria. Research on animals has suggested that heparin and related substances may prevent glomerular membrane thickening. However, it is not known whether heparin and related substances can prevent the onset of DKD and, therefore, be recommended for primary prevention of this condition. To assess the benefits and harms of heparin and related substances for preventing the onset of DKD. We searched the Cochrane Renal Group's Specialised Register and the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (Issue 2, 2009). We also searched MEDLINE (1966 to June 2009), EMBASE (1980 to June 2009), China Biological Medicine (CBM; 1979 to June 2009), VIP Chinese Science and Technique Journals Database (until June 2009), China National Infrastructure (CNKI) (until June 2009) and Wanfang database (until June 2009). Reference lists of nephrology textbooks, review articles and relevant studies were also searched. All relevant randomised controlled trials (RCTs) and quasi-RCTs looking at the benefits and harms of heparin and related substances for preventing the onset of DKD were eligible. We planned for two authors to extract data independently using a self-developed data extraction form and enter them into RevMan 5 software; for meta-analyses to be performed when more than one study provided data on a comparable outcome on sufficiently similar patients; for random-effects analyses to be performed whenever heterogeneity between results appeared to be present; and for standardised differences in mean outcome measures to be used due to the use of different scales and periods of treatment. No studies met our inclusion criteria. Rigorously well-designed, randomised, multi-centre, large-sample studies of heparin and related substances for preventing the onset of DKD are needed.
- 8 September 2010
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2010 (9) , CD005631
Heparin and related substances for preventing diabetic kidney disease
Diabetic kidney disease (DKD, also called diabetic nephropathy, DN) is the major cause of end-stage kidney disease (ESKD) in many countries and is associated with increased morbidity and mortality as compared to other causes of kidney disease. One of the pathological changes of DKD is the thickening of the glomerular basement membrane, mesangial expansion and proliferation. The presence of the glycosaminoglycan side chains of heparan sulfate proteoglycan, an important constituent of the glomerular basement membrane, is decreased in DKD proportionally to the increasing degree of proteinuria. Research on animals has suggested that heparin and related substances may prevent glomerular membrane thickening. However, it is not known whether heparin and related substances can prevent the onset of DKD and, therefore, be recommended for primary prevention of this condition. To assess the benefits and harms of heparin and related substances for preventing the onset of DKD. We searched the Cochrane Renal Group's Specialised Register and the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (Issue 2, 2009). We also searched MEDLINE (1966 to June 2009), EMBASE (1980 to June 2009), China Biological Medicine (CBM; 1979 to June 2009), VIP Chinese Science and Technique Journals Database (until June 2009), China National Infrastructure (CNKI) (until June 2009) and Wanfang database (until June 2009). Reference lists of nephrology textbooks, review articles and relevant studies were also searched. All relevant randomised controlled trials (RCTs) and quasi-RCTs looking at the benefits and harms of heparin and related substances for preventing the onset of DKD were eligible. We planned for two authors to extract data independently using a self-developed data extraction form and enter them into RevMan 5 software; for meta-analyses to be performed when more than one study provided data on a comparable outcome on sufficiently similar patients; for random-effects analyses to be performed whenever heterogeneity between results appeared to be present; and for standardised differences in mean outcome measures to be used due to the use of different scales and periods of treatment. No studies met our inclusion criteria. Rigorously well-designed, randomised, multi-centre, large-sample studies of heparin and related substances for preventing the onset of DKD are needed.